Efficacy of carrilizumab combined with chemotherapy in the treatment of advanced NSCLC and its effect on serum SCC-Ag,TIMP-1,D-D and miR-206
Wu Yuanyuan
Ma Dandan
Chen Jing
Guo Chao
Cao Jiangwei
Wang Haiyan
Li Dongjie
Wu Cuixiang
Li Runpu
Abstract：Objective To investigate the efficacy of carrilizumab combined with chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC)and its effects on serum squamous cell carcinoma antigen(SCC-Ag),tissue inhibitor of matrix metalloproteinase-1(TIMP-1),D-dimer and miR-206.Methods One hundred and ten patients with ad-vanced NSCLC admitted to the Oncology Department of Baoding Second Central Hospital from April 2022 to October 2023 were selected as the research subjects.They were randomly divided into a control group of 55 cases and an observation group of 55 cases using a random number table method.The control group received first-line chemotherapy,while the ob-servation group received additional treatment with Carilizumab on the basis of the control group.The treatment lasted for 21 days as one cycle,for a total of 4-6 cycles.Enzyme linked immunosorbent assay(ELISA)was used to detect the levels of serum SCC Ag,TIMP-1,and D-dimer,and real-time fluorescence quantitative PCR(qPCR)was performed to detect the ex-pression level of miR-206.Compare the clinical efficacy,serum indicators before and after treatment,levels of T lymphocyte subsets,and adverse reactions during treatment between two groups of patients.Results The total clinical effective rate of the observation group was higher than that of the control group(78.18％vs.60.00％,x2/P=4.257/0.039);Compared with before treatment,the serum levels of SCC Ag,TIMP-1,and D-dimer in both groups decreased after treatment,while the lev-els of miR-206 increased.The observation group showed a greater decrease/increase in each indicator than the control group(t/P=38.360,4.156,9.567,4.857/＜0.001);Compared with before treatment,CD4+T lymphocytes and CD4+/CD8+in-creased in both groups after treatment,while CD8+T lymphocytes decreased.Moreover,the observation group showed a greater decrease/increase in various indicators than the control group(t=6241,6.879,5.631,all P＜0.001);During the treat-ment period,the total incidence of adverse reactions in the observation group was lower than that in the control group(5.45％vs.21.82％,x2/P=6253/0.012).Conclusion Carrilizumab combined with chemotherapy is effective in the treatment of advanced NSCLC patients,which can effectively improve immune function,reduce serum SCC-Ag,TIMP-1 and D-dimer levels,and increase miR-206 levels.
Keywords：Advanced non-small cell lung cancerCarrilizumabChemotherapySquamous cell carcinoma antigenMatrix metalloproteinase tissue inhibitor-1D-dimerMicro RNA-206
Publication Date：2025-01-17
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)